Solid Biosciences (SLDB) Other Non-Current Liabilities (2018 - 2024)
Quarterly results put Other Non-Current Liabilities at $3.4 million for Q3 2024, changed N/A from a year ago — trailing twelve months through Sep 2024 was $3.4 million (changed N/A YoY), and the annual figure for FY2022 was $96000.0, changed.
Solid Biosciences has reported Other Non-Current Liabilities over the past 4 years, most recently at $3.4 million for Q3 2024.
- Other Non-Current Liabilities reached $3.4 million in Q3 2024 per SLDB's latest filing, up from $96000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $3.4 million in Q3 2024 and bottomed at $96000.0 in Q4 2022.
- Median Other Non-Current Liabilities over the past 3 years was $1.3 million (2020), compared with a mean of $1.6 million.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Solid Biosciences | 713.77 Mn | 333.09 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 3.40 Mn |
| Dec 31, 2022 | 96,000.00 |
| Dec 31, 2020 | 1.30 Mn |
| Dec 31, 2018 | 1.07 Mn |
| Sep 30, 2018 | 1.10 Mn |
| Jun 30, 2018 | 499,000.00 |
| Mar 31, 2018 | 365,000.00 |